Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jul 27, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
41.3%
-28.9% vs 52w high · +2.4% 1mo
Price (last ~year)
Novo Nordisk (NVO) is navigating increased generic competition for its semaglutide products following patent expirations, responding with the launch of lower-cost versions in South Africa and the initiation of a DKK 15 billion share buyback program. The company continues to report strong financial performance, with 24.0% year-over-year revenue growth and 67.1% earnings growth supported by an 83.2% gross margin. Shares currently trade at $48.77, reflecting a market capitalization of $215.70 billion and a P/E ratio of 11.67.
Valuation
- Market cap
- $215.70B
- P/E
- 11.67
- PEG
- 3.289
- P/B
- 6.96
- P/S
- 0.658
- EV/EBITDA
- 8.58
- Beta
- 0.36
- Analyst target
- $47.28
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $48.77
- 1-month
- +2.4%
- 3-month
- +18.5%
- RSI (14)
- 47
- vs SMA200
- +5.6%
- 52-wk position
- 41.3% -28.9% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Somewhat-Bearish Africa’s most developed pharmaceutical market reviews 12 Ozempic generics as drugmakers target Novo Nordisk’s dominance · 2026-07-21
- Somewhat-Bullish Novo Nordisk Ramps Up DKK 15 Billion Share Buyback Programme · 2026-07-21
- Neutral Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry · 2026-07-20
- Somewhat-Bullish Citi lifts Novo Nordisk target on strong GLP-1 pill launch · 2026-07-20
- Bullish Novo Nordisk launches cheaper Ozempic in South Africa · 2026-07-20
- Somewhat-Bullish Ozempic maker launches cheaper copy in Africa’s largest pharma market after court blocks unregistered Ozempic copies · 2026-07-18
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)